For small sponsors preparing for EU/UK launch, pharmacovigilance (PV) readiness is a frequent source of last-minute friction — especially where local requirements and points of contact differ by country.
However, this friction can be avoided by building the qualified person for pharmacovigilance (QPPV) office infrastructure in a ‘by-design’ way and using it as a commercial leverage.
For example, a local qualified person for pharmacovigilance (LQPPV) provides a way for the marketing authorisation holder (MAH) to demonstrate a commitment to country-level safety surveillance and provide expertise in local regulations. Having an LQPPV in place helps the MAH stay inspection-ready and keep momentum during market entry (especially when you don’t yet have a full European infrastructure).
This guide explains what the LQPPV role is (and isn’t), how legal responsibilities differ across EU and UK markets, and how an outsourced or embedded local QPPV can de-risk early drug commercialisation decisions for emerging and growth-stage companies.
Contents:
1. What are the local QPPV requirements across EU/UK markets
Although the term ‘local qualified person for pharmacovigilance’ is used in industry, it is not a single, harmonised EU legal role in the same way as the EU QPPV is.
An LQPPV is a statutory requirement in certain EU/EEA Member States, where national legislation mandates the appointment of an in‑country PV‑responsible person with defined responsibilities and authority to support the EU QPPV and ensure local PV compliance.
In the UK, MHRA guidance confirms that every UK MAH must have a UK QPPV available, and if the QPPV is not located in the UK (i.e. if this role is fulfilled by an EU-based QPPV), a national contact person (NCP) for PV is needed (with defined access and responsiveness expectations).
A local safety officer (LSO), by contrast, is not a legal requirement, but companies may appoint one voluntarily to ensure local‑language communication, local regulatory interaction and operational PV support in markets where no formal local PV role is mandated.
2. When do you need a local QPPV?
You’re most likely to need a local QPPV in three scenarios:
- UK QPPV is not UK-based. The UK framework anticipates a national contact person where the QPPV is located outside the UK and sets expectations around access to the PV system and timely responses to MHRA queries/inspections.
- Specific EU Member State expectations. Requirements vary by country. The EMA publishes a Member State overview capturing whether there is a legal requirement for a national contact person or where it may be requested.
- Local language/regulatory interface needs (even where not strictly mandated). A national authority may expect a local interface who can operate in-country, in-language and at local working hours. The Netherlands is a commonly cited example of explicit national expectations (including Dutch language capability and defined liaison with the QPPV).
It’s also worth noting that, for a marketing authorisation holder, ‘local’ requirements are a country-by-country question. So, build the local contact model early — ideally before the first commercial supply — so you’re not retrofitting governance mid-launch.
3. What does a local QPPV actually do?
While the global/EU QPPV retains overall legal responsibility for the company’s PV system, a local qualified person for pharmacovigilance (or national PV contact) typically supports by:
- Acting as the legally designated national PV representative and the MAH’s official local contact, where required.
- Ensuring compliance with country-specific PV obligations and reporting requirements.
- Liaising with the National Competent Authority (NCA) and managing local-language safety communications, including urgent requests.
- Providing national PV oversight and escalating relevant safety information, signals and compliance updates to the EU QPPV.
- Coordinating local adverse event reporting by receiving and processing individual case safety reports (ICSRs), completing follow-up and ensuring timely submission.
- Preparing, submitting or coordinating local PV regulatory submissions, including aggregate reports, local risk management plan (RMP) requirements and safety-related filings.
- Monitoring ongoing compliance with national legislation, including local PV procedures, additional risk minimisation measures (aRMMs) and local reporting rules.
- Delivering local PV training for internal teams, affiliates and third parties handling safety data.
- Supporting PV inspections and audits by maintaining local documentation and acting as the national inspection point of contact.
- Representing the MAH on product safety matters at the national level by supporting local risk management activities and safety initiatives.
When there isn’t a clearly defined local contact, the gaps tend to show up in response times to regulatory enquiries, clarity of responsibilities and inspection readiness.
4. Where does accountability sit in EU/UK pharmacovigilance?
Before you decide whether you need a local role, it helps to be clear on where accountability sits. In the EU and UK, the organisation named on the licence — the MAH — remains responsible for the pharmacovigilance system and for meeting the conditions of the marketing authorisation.
All UK and EU/EEA MAH’s must appoint (at the time of submitting the marketing authorisation application) a QPPV: a ‘natural person’ residing in the UK or EU/EEA, who is ‘permanently and continuously available’ to fulfil their legal obligations of maintaining full oversight of the MAH’s PV system, ensuring effective and compliant safety process and regulator communications.
That requirement doesn’t change if you use third-party support.
PV activities can be, and often are, outsourced (and in some launch models, work with partners who support parts of the PV operation), but regulators will still expect the marketing authorisation holder to demonstrate oversight, inspection readiness and the ability to respond quickly to safety-related requests.
In that context, the value of a local QPPV is practical rather than symbolic: it strengthens local responsiveness, clarifies who does what in each market and helps you avoid last-minute rework as you move through early drug commercialisation and scale your EU/UK presence.
5. How to appoint and embed a local QPPV
Once you’ve confirmed where a local role is required (or strongly expected), the next step is making sure it’s set up in a way that supports compliance without adding complexity or friction.
The steps below outline how to appoint and embed a local qualified person for pharmacovigilance so that responsibilities, access and oversight are clear from day one.
Map where you need a local contact
Start with your licence procedure (centralised or decentralised); if the MAH has a centralised approval, the expectation is that they will comply with full regional PV regulations. Secondary to the licence type is the target markets and commercialisation strategy. Once this is known, the MAH can confirm country expectations (using the EU Member State overview and national guidance documents).
Consider the benefits of ‘regional hubs’
Compliance does not need to be complicated, and it can be operationally ‘smart’ to utilise regional hubs for local PV support, further embedding efficiency and consistency in the PV operations and leveraging local expertise and knowledge.
Define clear roles and responsibilities
Clear organisational charts, delegations and reporting lines help ensure the national (or regional) PV contact communicates effectively with the rest of the PV operational team. Align interfaces with your global/EU QPPV and quality system.
Put the right access in place
Make sure the local role has defined access to systems, standard operating procedures, safety data flows and escalation pathways so that responses to authorities are fast and consistent (and the appropriate QPPV and MAH oversight is maintained).
Establish governance and oversight
Set the cadence for touchpoints (e.g. weekly PV ops touchpoint and monthly oversight review), define inspection readiness routines, and document delegation and escalation pathways clearly.
Notify authorities where required
Where national filings/registrations apply, ensure the contact details are current and change control is documented (this is often tested during inspections).
Note that country requirements can change and may be applied differently depending on the product, route and local authority practice, so it’s essential to validate requirements per market during launch planning.
6. Why outsourcing the local QPPV role de-risks market entry for small sponsors
For emerging biotech and pharma companies moving into EU/UK launch, outsourcing a local qualified person for pharmacovigilance can reduce risk in ways that directly support commercialisation:
- Fewer launch-critical delays: local authority responses don’t bottleneck behind a stretched global team.
- Improved inspection readiness: documentation, access and escalation are established from day one — not built under pressure.
- Scalable infrastructure: you add capability without building a full in-house PV organisation before revenue.
This is particularly relevant when your EU/UK operating model involves a partner acting as an MAH — temporarily or long term — while you build your own presence.
Where a local QPPV (or national PV contact) is needed, an outsourced/embedded approach can be designed to:
- Fit your launch timeline.
- Align with your QPPV oversight model.
- Support compliance expectations while you retain control of the asset and the broader marketing authorisation
For late-stage and commercial-ready companies, TMC Commercial provides flexible, full-service drug commercialisation solutions in the EU and UK, and has the specialist expertise to act as a marketing authorisation holder as a bridge or long-term model. We can also act as a QPPV and coordinate with PV teams for ongoing safety monitoring, signal detection and risk management.
If you’re planning EU/UK launch and want to clarify what local pharmacovigilance roles you need — and how to set them up without adding operational burden — TMC Commercial can help. Speak to our team today at connect@tmcpharma.com to discuss your requirements.